DBV Technologies S.A. (DBVT)
NASDAQ: DBVT · Real-Time Price · USD
13.06
+0.16 (1.20%)
Nov 28, 2025, 4:00 PM EST - Market closed
DBV Technologies Revenue
DBV Technologies had revenue of $2.77M in the quarter ending September 30, 2025, with 158.77% growth. This brings the company's revenue in the last twelve months to $5.50M, down -56.04% year-over-year. In the year 2024, DBV Technologies had annual revenue of $4.15M, down -73.61%.
Revenue (ttm)
$5.50M
Revenue Growth
-56.04%
P/S Ratio
86.52
Revenue / Employee
$50,018
Employees
110
Market Cap
476.05M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4.15M | -11.58M | -73.61% |
| Dec 31, 2023 | 15.73M | 10.88M | 224.69% |
| Dec 31, 2022 | 4.84M | -864.00K | -15.14% |
| Dec 31, 2021 | 5.71M | -5.57M | -49.38% |
| Dec 31, 2020 | 11.28M | -3.43M | -23.33% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
DBVT News
- 17 days ago - DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years - GlobeNewsWire
- 24 days ago - DBV Technologies to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference - GlobeNewsWire
- 25 days ago - DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer - GlobeNewsWire
- 4 weeks ago - DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors - GlobeNewsWire
- 4 weeks ago - DBV Technologies to Participate in Upcoming ACAAI 2025 Annual Scientific Meeting - GlobeNewsWire
- 4 weeks ago - DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq - GlobeNewsWire
- 2 months ago - DBV Technologies Announces Resignation of Board Member - GlobeNewsWire
- 3 months ago - DBV Technologies Establishes an At-The-Market (ATM) Program on Nasdaq - GlobeNewsWire